Veradermics, Incorporated (MANE)
NYSE · Healthcare · Biotechnology
$118.87+1.81%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $5.0B
- 52-week range
- $32.00 – $131.24
- 52-week change
- +209.30%
- EPS (trailing)
- −$4.24
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$70.0M
- Diluted EPS
- −$111.91
- Free cash flow
- −$71.6M
From the company’s annual report on SEC EDGAR.
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Headquarters: New Haven, United States · 37 employees · veradermics.com